Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MODICON 21 vs DEMULEN 1/35-28
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) from pituitary via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; induces endometrial thinning.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy
One tablet (norethindrone 0.5 mg and ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days, followed by 7 drug-free days.
One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life: 12–18 hours; clinical context: steady-state reached after 3–5 days of daily dosing
Ethinyl estradiol: 17.4 ± 5.6 h (terminal); norethindrone: 10.9 ± 1.6 h (terminal); clinically, steady-state achieved within 5-7 days.
Ethinyl estradiol undergoes hepatic CYP3A4-mediated hydroxylation and conjugation; norethindrone is reduced and conjugated in liver.
Ethinylestradiol undergoes hepatic metabolism via CYP3A4; norethindrone undergoes reduction and conjugation in the liver.
Renal (80% as metabolites, 20% unchanged); biliary/fecal (minor, <5% total)
Renal 50% (metabolites), fecal 50% (biliary elimination of conjugates).
Ethinylestradiol: 97% bound to albumin; Norethindrone: 80% bound to albumin and SHBG
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 93% bound to albumin and SHBG.
Ethinylestradiol: 2–4 L/kg; Norethindrone: 3–5 L/kg; large Vd indicates extensive tissue distribution
Ethinyl estradiol: 2.3-4.3 L/kg; norethindrone: 4.4 L/kg; indicates extensive tissue distribution.
Oral: 40–60% (first-pass metabolism reduces systemic availability)
Ethinyl estradiol: 40-45% (oral; first-pass metabolism); norethindrone: 64-67% (oral).
No dose adjustment required for chronic kidney disease. Contraindicated in acute renal failure or severe renal impairment (GFR <30 m L/min) due to potential fluid retention and electrolyte disturbances.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
Contraindicated in acute hepatic disease, hepatic adenomas, or impaired liver function (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), use with caution; monitor liver function.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Avoid use if liver function tests are abnormal.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal minors established; dose same as adults (one tablet daily for 21 days, then 7 days off).
Not indicated for use before menarche. For postmenarchal adolescents, use same dosing as adults (one tablet orally once daily).
Not indicated for use in postmenopausal women. No specific dose adjustments for elderly due to lack of indication; consider increased risk of cardiovascular and thrombotic events in women over 35 who smoke.
Not indicated for use in postmenopausal women.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day); women >35 years who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and smoking intensity. Women over 35 who smoke should not use this product.
Thrombotic disorders (thrombophlebitis, venous thromboembolism, arterial thromboembolism),Cardiovascular disease (e.g., myocardial infarction, stroke) especially in smokers >35,Liver disease (e.g., hepatic adenoma, hepatocellular carcinoma),Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid metabolic effects,Ocular lesions (e.g., retinal thrombosis),Headache/migraine,Bleeding irregularities,Depression
Increased risk of thromboembolic disorders,Cerebrovascular disease,Myocardial infarction,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate/lipid effects,Headache,Uterine bleeding,Ocular lesions,Depression
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking and age >35 years
Known or suspected pregnancy,Current or past thrombosis,Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms,Major surgery with prolonged immobilization,Known or suspected breast cancer,Endometrial cancer or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenomas or carcinomas,Active liver disease,Known hypersensitivity to any component
No specific food restrictions; however, grapefruit juice may increase estrogen levels slightly (theoretical). Maintain consistent intake of folate-rich foods as oral contraceptives may lower folate levels. Avoid St. John's wort (herbal) as it reduces contraceptive efficacy.
No significant food interactions. Grapefruit juice has minimal effect on ethinyl estradiol; no restriction needed. Avoid excessive alcohol, which may impair adherence or increase liver enzymes. St. John's wort reduces contraceptive efficacy and should be avoided.
Modicon 21 is a combination oral contraceptive. First trimester: Epidemiologic studies have not shown an increased risk of birth defects with inadvertent exposure. Second and third trimesters: Use is not indicated during pregnancy; fetal and neonatal risks include cardiovascular and genitourinary anomalies, though data are limited and confounded by maternal condition.
First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and oral clefts (OR ~1.3-1.6). Second/third trimester: Androgenization of female fetus (clitoromegaly, labial fusion) due to progestin component; possible association with hypospadias in males with first-trimester exposure. Avoid use in pregnancy.
Combination hormonal contraceptives reduce milk production and may pass into breast milk. M/P ratio not established. Use in breastfeeding is generally not recommended until breastfeeding is well-established (typically after 6 weeks postpartum).
Excreted in breast milk; estimated infant dose <1% of maternal dose. M/P ratio not available for ethinyl estradiol/ethynodiol diacetate. May reduce milk production and quality. Use only if benefits outweigh risks; lowest effective dose recommended.
Not applicable as Modicon 21 is contraindicated during pregnancy. No dose adjustment is needed.
Contraindicated in pregnancy; no dose adjustment applicable. If inadvertently used, discontinue immediately.
MODICON 21 (norethindrone/ethinyl estradiol) is a monophasic oral contraceptive. Administer starting on day 1 of menstrual period (Sunday start or day 1 start). Breakthrough bleeding is common in first cycles; sustained bleeding warrants evaluation. Missed dose protocol: if one pill is missed, take it ASAP and continue schedule; if two or more missed, use backup contraception for 7 days. Advise against smoking due to increased thrombotic risk, especially in women over 35. Assess for contraindications: history of DVT/PE, migraine with aura, breast cancer, liver disease, uncontrolled hypertension, etc. Drug interactions: rifampin, anticonvulsants (phenytoin, carbamazepine), St. John's wort may reduce efficacy.
DEMULEN 1/35-28 (ethinyl estradiol 35 mcg + ethynodiol diacetate 1 mg) is a monophasic combined oral contraceptive. Its progestin has mild androgenic activity, which may be less favorable for acne-prone patients compared to third-generation pills. The 28-day pack includes 21 active pills and 7 inert pills. Counsel patients to take at the same time daily; missed pills increase breakthrough bleeding and pregnancy risk. It may be used off-label for cycle control in patients without contraindications.
Take one pill daily at the same time each day for 21 days, then 7 days off.,If you miss a pill, follow the missed dose instructions in the package insert.,Use backup contraception (e.g., condoms) if you miss two or more pills.,Do not smoke while taking this medication; smoking increases risk of blood clots.,Report any sudden severe headache, chest pain, leg swelling, or vision changes immediately.,You may experience irregular bleeding, nausea, or breast tenderness initially.,This medication does not protect against sexually transmitted infections.,Check with your doctor before starting any new medications, including herbal supplements.
Take one pill daily at the same time, preferably after dinner to reduce nausea.,If you miss one pill, take it as soon as remembered; if missed more than one, use backup contraception for 7 days.,Smoking increases risk of blood clots; especially dangerous if over 35 and smokes.,Some antibiotics (e.g., rifampin) and antiseizure medications may reduce effectiveness.,Report any signs of blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,Breakthrough bleeding is common in first 3 cycles; if persistent, contact your healthcare provider.,Do not use if pregnant; if pregnancy occurs, stop immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MODICON 21 vs DEMULEN 1/35-28, answered by our medical review team.
MODICON 21 is a Combination Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) from pituitary via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; induces endometrial thinning.. DEMULEN 1/35-28 is a Combination Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MODICON 21 and DEMULEN 1/35-28 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MODICON 21 is: One tablet (norethindrone 0.5 mg and ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days, followed by 7 drug-free days.. The standard adult dose of DEMULEN 1/35-28 is: One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MODICON 21 and DEMULEN 1/35-28 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MODICON 21 is classified as Category C. Modicon 21 is a combination oral contraceptive. First trimester: Epidemiologic studies have not shown an increased risk of birth defects with inadvertent exposure. Second and third. DEMULEN 1/35-28 is classified as Category C. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and oral clefts (OR ~1.3-1.6). Second/third trimester: Androgenization of female fetus (clitoromeg. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.